On July 3, 2018, Maine’s highest court, the Maine Supreme Judicial Court, affirmed a summary judgment entered in favor of Copan Italia S.p.A. and against Puritan Medical Products Company, LLC on Puritan’s state law claim for bad faith assertion of patent infringement.
04 June 2018
Brescia, Italy – June 1st, 2018 – COPAN Italia S.p.A. and its U.S. subsidiary, COPAN Diagnostics Inc. announced today that they have filed a lawsuit against Puritan Medical Products Co., LLC and Puritan Diagnostics LLC, in the United States District Court for the District of Maine for infringement of U.S. Patent No. 8,114,027, U.S. Patent No. 8,317,728, U.S. Patent No. 8,979,784, U.S. Patent No. 9,011,358, and U.S. Patent No. 9,173,779.
Daniele Triva Memorial Post-Doctoral Fellowship in Diagnostic Clinical Microbiology
This one-year post-doctoral fellowship supports the successful candidate for an intense, applied and project-oriented fellowship experience in diagnostic clinical microbiology under the supervision of two McMaster University faculty, in the setting of one of Canada’s busiest and most innovative clinical microbiology laboratories.
Daniele Triva was a brilliant and visionary leader of Copan Italia, whose innovation in pre-analytic methods, liquid microbiology, and laboratory automation forever changed how microbiology laboratories diagnose infectious diseases. For over 20 years, McMaster University, the Hamilton Regional Laboratory Medicine Program (HRLMP) and Copan Italia have collaborated in diagnostic research and implementation of automation in the clinical laboratory. Today, HRLMP is renowned for its leadership and expertise in virology, molecular diagnostics and laboratory automation, providing clinical microbiology services to over a dozen Ontario hospitals. This unique fellowship continues this long-standing collaboration.
Dicember 05, 2017 - Murrieta CA
Recent multicenter study by Dr. Carey-Ann D. Burnham et al adds another application to the growing number of uses and endorsements for COPAN’s widely popular ESwab®. ESwab® comprises of 1ml of liquid Amies and a flocked swab that completely elutes the sample into the preservation medium. Its versatility and universal appeal simplifies sample collection by minimizing the plethora of specimen collection swabs that need to be stocked by medical centers and clinics in favor of a single multipurpose bacteriology swab.
Copan Italia - 9 November, 2017 - Brescia, Italy
Copan Italia SpA and Shinji Matsuura proudly announce the formation of a joint venture for the strategic promotion and distribution of Copan’s Liquid Based Microbiology™ (LBM®) range in Japan.
Murrieta, CA – September 28, 2017
Apparently, many Americans spend the holidays doing more than hanging up stockings and trimming the tree. September happens to wear the noteworthy title of “most popular birth month in the United States”. Count back nine months and … you get the point.
Murrieta, CA – September 14, 2017
It isn’t every day that a company hits four milestones with the placement of one system. But that is exactly what happened last month at the University Health Network/Sinai Health System’s Department of Microbiology in Toronto, Ontario when COPAN installed WASPLab®, a fully automated specimen processor and work-up system for microbiology, which comprises robotic culture and incubation of specimens, digital imaging and artificial intelligence to assist interpretation and reporting of patient results.
Murrieta, CA – July 24, 2017
After a successful launch at the American Society for Microbiology (ASM) Microbe 2017, COPAN is showcasing PhenoMATRIX™ to a wider audience at the American Association for Clinical Chemistry (AACC) annual meeting at the San Diego Convention Center from August 1 through August 3.
Tampa, FL – July 09, 2017
The "MilkyWay™" is heading to the Sunshine State
New Orleans, CA – June 14, 2017
NEW ORLEANS — A novel home-based self-sampling vaginal swab for detection of STDs produced the same results as a swab used under the supervision of a gynecologist and was preferred by 80% of patients, according to the results of a study presented at ASM Microbe.
Murrieta, CA – April 21st, 2017
When it comes to stool, sometimes less is more. A recent study published in the Journal of Clinical Microbiology titled “Evaluation of the New FecalSwab™ to Maintain Stability of Stool Samples Submitted for Molecular Tests” concluded that this is particularly true when taking advantage of the convenience and accuracy of COPAN’s latest product addition: FecalSwab™. The study, released on March 15, 2017 set out to determine the most effective, rapid and least invasive method to collect stool samples and quickly treat patients suffering from gastrointestinal diseases.
Murrieta, CA May 5th, 2017
GI Pathogens can be difficult to detect due to the lack of sensitivity and speed experienced with traditional methods and patients having trouble providing a timely specimen. To help remedy these issues COPAN’s FecalSwab™ (FS) has been the focal point of several recent evaluations. As a kit, FecalSwab™ comes with a regular COPAN flocked swab (FLOQSwabs™) and 2 mL of Cary-Blair medium. Many clinicians have considered using the flocked swab as a rectal swab, in scenarios where timely access to a sample is crucial, and ability to collect a fresh stool is unmanageable. There is an unmet clinical need in pediatric settings when the patient shows up with acute symptoms and a sample needs to be immediately obtained for testing. In a continuation of an earlier study, Dr. Chapin and her team presented Comparison of Results Obtained with the FilmArray GI Panel Using Rectal Swabs and Cary-Blair Stool from Patients with Gastroenteritis in the Pediatric Emergency Dept., which entailed studying the use of FecalSwab™ as a rectal collection device that could be administered upon patient visit in conjunction with a widely accepted rapid detection assay, the FilmArray Gastrointestinal Panel (BioFire Diagnostics). While FecalSwab™ has had FDA clearance since Spring of 2015, the use of FS as a rectal swab collection device used in conjunction with a molecular FilmArray GI Panel has not been cleared by the FDA.
Murrieta, CA April 28th, 2017
When you got it, flaunt it. It appears the use of FecalSwab™ is popping up everywhere.
A brandnew study presented at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria examined the use of FecalSwab™ for yet another major molecular diagnostic platform, the Seegene Allplex gastrointestinal multiplex PCR. In this study, Rebbapragada et al examined FecalSwab’s compatibility with the Seegene’s molecular chemistry, and FecalSwab’s convenience and utility when used with an automated pipetting platform employed within the assay. The study showed FecalSwab’s improved limit of detection when compared to traditional enteric transport media.
22-25 April 2017
VISIT COPAN AT ECCMID 2017, BOOTH #14
Copan Italia SPA
Seleziona 1 candidato che sarà assegnatario di borsa di studio aziendale per il profilo di Tecnico specializzato sul tema dell’adaptive manufacturing applicato alle apparecchiature per esami di laboratorio.
2 - SEP - 2016
COPAN SHOWCASE: A New Era for Crime Scene Sample Collection Devices
Tuesday 27th September 2016 - 5.30pm to 7.30pm
Hyatt Regency in Minneapolis, MN, Room Greenway H-J
12 - MAY - 2016
With the recent implementation of WASPLab™ and digital microbiology, COPAN Diagnostics, Inc. is pleased to announce a strategic alliance with TriCore Reference Laboratories.
23 - FEB - 2016
Although the system is compatible with most swab types, several customers have successfully validated the use of Copan FLOQSwabs™ with iSWAB - ID and have combined the products in their workflow for optimal results. We highly recommend the use of Copan FLOQSwabs™ with Mawi's iSWAB - ID sample collection system.
17 - FEB - 2016
Murrieta, CA – COPAN Diagnostics, Inc. is pleased to announce groundbreaking results of a multi-center study titled “Automated Scoring of Chromogenic Media for the Detection of MRSA using the WASPLab Image Analysis Software” recently published in the Journal of Clinical Microbiology. The study performed by Faron et al (2015) is unique in its class, testing 57,690 samples and demonstrating that the WASPLab™ image analysis software can automatically detect and segregate positive from negative MRSA samples using chromogenic agar with a sensitivity of 100%, and a specificity of 90-96% (varying by location). In fact, the software was able to detect an additional 153 positive MRSA patients that were missed by manual reading. Locations of the participating laboratories spanned across the globe including Italy, The Netherlands, Canada, and the United States.
3 - SEP -2015
A recent study conducted at Tampa General Hospital in Florida, and published in the Journal of Clinical Microbiology, tested the use of ESwab™ with the BD Max MRSAXT and BD Max StaphSR assays. The study, consisting of 255 samples collected using ESwab™ showed that the assays have exceptional sensitivity and specificity for detecting MRSA and S. aureus, respectively.